Перейти к главному меню навигации Перейти к основному контенту Перейти к нижнему колонтитулу сайта

№ 1 (2022)

НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА

Биполярное аффективное расстройство. Новые возможности терапии

https://doi.org/10.21265/PSYPH.2022.60.1.005

Опубликован 2022-03-30

  • Наталия Николаевна Петрова

Наталия Николаевна Петрова
Санкт-Петербургский государственный университет

Аннотация

Актуальность. Биполярное аффективное расстройство относится к тяжелым хроническим психическим расстройствам, встречается со значительной частотой, ассоциировано с нарушением социального функционирования и риском суицида. Цель обзора литературы – характеристика распространенности, подходов к диагностике и антипсихотической терапии биполярного аффективного расстройства, в частности, возможностей применения антипсихотика третьего поколения карипразина.
Методы. Проведен систематический обзор литературы в PubMed и Google с использованием различных комбинаций ключевых слов. Списки литературы всех выявленных публикаций проверены вручную с целью поиска дополнительных статей и на предмет соответствия рассматриваемой проблеме. Критерии включения: релевантные полнотекстовые статьи, систематические обзоры, метаанализы по проблеме биполярного аффективного расстройства и применения карипразина в терапии биполярного расстройства I типа.
Результаты. Приведены современные представления о распространенности, клинических характеристиках, факторах риска суицида, потенциальных биомаркерах у пациентов с биполярным расстройством с акцентом на антипсихотическую терапию заболевания, в частности, результаты доказательных исследований применения карипразина при маниакальных, депрессивных и смешанных эпизодах биполярного расстройства I типа.
Заключение. Применение антипсихотика третьего поколения карипразина эффективно и безопасно у пациентов с биполярным аффективным расстройством I типа.

Ключевые слова

биполярное аффективное расстройство, эпидемиология, диагностика, клиническая картина, антипсихотическая терапия, карипразин

PDF

Библиографические ссылки

  1. Grande I., Berk M., Birmaher B., Vieta E. Bipolar disorder // Lancet. – 2016. – Vol. 387 (10027). – Pp. 1561–1572.
  2. Joslyn C., Hawes D.J., Hunt C., Mitchell P.B. Is age of onset associated with severity, prognosis, and clinical features in bipolar disorder? A meta-analytic review // Bipolar Disord. – 2016. – Vol. 18. – Pp. 389–403.
  3. Angst J., Sellaro R. Historical perspectives and natural history of bipolar disorder // Biol Psychiatry. – 2000. Vol. 48. – Pp. 445–57.
  4. Goodwin G.M., Geddes J.R. What is the heartland of psychiatry? // Br J Psychiatry. – 2007. – Vol. 191. – Pp. 189–191. – DOI: 10.1192/bjp.bp.107.036343
  5. Blanco C., Compton W.M., Saha T.D. et al. Epidemiology of DSM-5 bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III // J Psychiatr Res. – 2017. – Vol. 84. – Pp. 310–317.
  6. Daveney J., Panagioti M., Waheed W., Esmail A. Unrecognized bipolar disorder in patients with depression managed in primary care: A systematic review and meta-analysis // Gen Hosp Psychiatry. – 2019. – Vol. 58. – Pp. 71–76.
  7. Diler R.S., Goldstein T.R., Hafeman D. et al. Characteristics of depression among offspring at high and low familial risk of bipolar disorder // Bipolar Disord. – 2017. – Vol. 19. – Pp. 344–352.
  8. Vieta Е., Salagre Е., Grande I. Early intervention in bipolar disorder // American Journal of Psychiatry – 2018. – Vol. 175 (5). – Pp. 411–426.
  9. Judd L.L., Akiskal H.S., Schettler P.J. et al. Psychosocial disability in the course of bipolar I and II disorders: A prospective, comparative, longitudinal study // Arch Gen Psychiatry. – 2005. – Vol. 62. – Pp. 1322–1330.
  10. Rosa A.R., Reinares M., Michalak E.E. et al. Functional impairment and disability across mood states in bipolar disorder // Value Health. – 2010. – Vol. 13. – Pp. 984–988.
  11. Westman J., Hällgren J., Wahlbeck K. et al. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden // BMJ Open. – 2013. – Vol. 3. – Pp. 1–8.
  12. Valtonen H.M., Suominen K., Mantere O. et al. Prospective study of risk factors for attempted suicide among patients with bipolar disorder // Bipolar Disord. – 2006. – Vol. 8. – Pp. 576–585.
  13. Miskowiak K.W., Burdick K.E., Martinez-Aran A. et al. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians // Bipolar Disord. – 2018. – Vol. 20. – Pp. 184–194.
  14. McIntyre R.S., Berk M., Brietzke E., Goldstein B.I., López-Jaramillo C., Kessing L.V., Malhi G.S., Nierenberg A.A., Rosenblat J.D., Majeed A., Vieta E., Vinberg M., Young A.H., Mansur R.B. Bipolar disorders // Lancet. – 2020. – Vol. 396 (10265). – Pp. 1841–1856. – DOI: 10.1016/S0140-6736(20)31544-0; PMID: 33278937.
  15. Vieta E., Berk M., Schulze T.G. et al. Bipolar disorders // Nat Rev Dis Primers. – 2018. – Vol. 4. – Art. 18008
  16. Rowland T.A., Marwaha S. Epidemiology and risk factors for bipolar disorder // Ther Adv Psychopharmacol. – 2018. – Vol. 9. – Pp. 251–269.
  17. Miller S., Dell’Osso B., Ketter T.A. The prevalence and burden of bipolar depression // J Affect Disord. – 2014. – Vol. 169, suppl. 1. – S. 3–11.
  18. Kupka R.W., Altshuler L.L., Nolen W.A. et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder // Bipolar Disord. – 2007. – Vol. 9 (5). – Pp. 531–535.
  19. Judd L.L., Akiskal H.S., Schettler P.J. et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder // Arch Gen Psychiatry. – 2002. – Vol. 59 (6). – Pp. 530–537.
  20. Tondo L., Vázquez G.H., Baldessarini R.J. Depression and mania in bipolar disorder // Current Neuropharmacology. – 2017. – Vol. 15. – Pp. 353–358.
  21. Kessler R.C., Akiskal H.S., Ames M. et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers // Am J Psychiatry. – 2006. – Vol. 163 (9). – Pp. 1561–1568.
  22. Simon G.E., Ludman E.J., Unutzer J., Operskalski B.H., Bauer M.S. Severity of mood symptoms and work productivity in people treated for bipolar disorder // Bipolar Disord. – 2008. – Vol. 10 (6). – Pp. 718–725.
  23. Hu J., Mansur R., McIntyre R.S. Mixed specifier for bipolar mania and depression: Highlights of DSM-5 changes and implications for diagnosis and treatment in primary care // Prim Care Companion CNS Disord. – 2014. – Vol. 16 (2). – PCC.13r01599. – DOI: 10.4088/PCC.13r01599; Epub 2014 Apr 17; PMID: 25133063; PMCID: PMC4116292.
  24. Kapczinski F., Magalhães P.V., Balanzá-Martinez V. et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report // Acta Psychiatr Scand. – 2014. – Vol. 130 (5). – Pp. 354–363. – DOI: 10.1111/acps.12305; Epub 2014 Jun 25; PMID: 24961757.
  25. Wise T. et al. Voxel-based meta-analytical evidence of structural disconnectivity in major depression and bipolar disorder // Biol Psychiatry. – 2016. – Vol. 79. – Pp. 293–302
  26. Hibar D.P. et al. Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group // Mol Psychiatry. – 2017. – Published online May 2, 2017. – DOI: 10.1038/mp.2017.73
  27. Brown N.C. et al. An updated meta-analysis of oxidative stress markers in bipolar disorder // Psychiatry Res. – 2014. – Vol. 218. – Pp. 61 - 68.
  28. Andreazza A.C. et al. Bipolar disorder as a mitochondrial disease // Biol Psychiatry. – 2017. – Published online September 28, 2017. – DOI: 10.1016/j.biopsych.2017.09.018
  29. Goldsmith D.R., Rapaport M.H., Miller B.J. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression // Mol Psychiatry. – 2016. – Vol. 21 (12). – Pp. 1696–1709. – DOI: 10.1038/mp.2016.3; Epub 2016 Feb 23; PMID: 26903267; PMCID: PMC6056174.
  30. Melo M.C.A., Abreu R.L.C., Linhares Neto V.B., de Bruin P.F.C., de Bruin V.M.S. Chronotype and circadian rhythm in bipolar disorder: A systematic review // Sleep Med Rev. – 2017. – Vol. 34. – Pp. 46–58. – DOI: 10.1016/j.smrv.2016.06.007; Epub 2016 Jul 1; PMID: 27524206.
  31. Ashok A.H., Marques T.R., Jauhar S., Nour M.M., Goodwin G.M., Young A.H., Howes O.D. The dopamine hypothesis of bipolar affective disorder: The state of the art and implications for treatment // Mol Psychiatry. – 2017. – Vol. 22 (5). – Pp. 666–679. – DOI: 10.1038/mp.2017.16; Epub 2017 Mar 14; PMID: 28289283; PMCID: PMC5401767.
  32. Harrison P.J., Geddes J.R., Tunbridge Е.M. The Emerging Neurobiology of Bipolar Disorder // Trends in Neurosciences. – 2018. – Vol. 41 (1). – DOI: 10.1016/j.tins.2017.10.006
  33. Мосолов С.Н., Костюкова Е.Г. Диагностика и лечение биполярного аффективного расстройства. Психиатрия: национальное руководство / под ред. Н.Г. Незнанова, Ю.А. Александровского. – М.: ГЭОТАР-Медиа, 2018. – C. 347–378.
  34. Костюкова Е.Г. Расширение показаний антипсихотиков второго поколения: от шизофрении к биполярному аффективному расстройству // Современная терапия психических расстройств. – 2020. – № 3. – С. 29–37. – DOI: 10.21265/PSYPH.2020.79.73.004
  35. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. 2014. – Available at: https://www.nice.org.uk/guidance/cg185 (accessed February 15, 2022).
  36. Agency of Healthcare Research and Quality. 2018, Treatment for bipolar disorder in adults: A systematic review; comparative effectiveness review number 208. – AHRQ Publication No. 18-EHC012-EF. Available at: https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-208-bipolar-report.pdf (accessed February 15, 2022).
  37. Jauhar S., Young A.H. Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy // Int J Bipolar Disord. – 2019. – Vol. 7. – P. 10. – DOI: 10.1186/s40345-019-0145-0
  38. PRNewswire. 2019. Allergan and Gedeon Richter receive U.S. FDA approval for expanded use of VRAYLAR® (cariprazine) in the treatment of bipolar depression [press release]. Available at: https://www.prnewswire.com/news-releases/allergan-and-gedeon-richterreceive-us-fda-approval-for-expanded-use-of-vraylar-cariprazine-in-the-treatmentof-bipolar-depression-300857106.html (accessed February 15, 2022).
  39. Keramatian K., Chakrabarty T., Saraf G., Yatham L.N. New developments in the use of atypical antipsychotics in the treatment of bipolar disorder: A systematic review of recent randomized controlled trials // Current Psychiatry Reports. – 2021. – Vol. 23 (7). – DOI: 10.1007/s11920-021-01252-w
  40. Петрова Н.Н., Софронов А.Г. Антипсихотики: от первого к третьему поколению // Формулы фармацеи. – 2020. – № 4 (4). – С. 82–89. – DOI: 10.17816/phf55260
  41. Инструкция по медицинскому применению лекарственного препарата Реагила® РУ: ЛП-005405 от 18.03.2019. URL: http://www.grls.rosminzdrav.ru (дата обращения 18.02.2022).
  42. Durgam S., Starace A., Li D. et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial // Bipolar Disord. – 2015. – Vol. 17 (1). – Pp. 63–75.
  43. Calabrese J.R., Keck P.E. Jr., Starace A., Lu K., Ruth A., Laszlovszky I., Németh G., Durgam S. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study // J Clin Psychiatry. – 2015. – Vol. 76 (3). – Pp. 284–292. – DOI: 10.4088/JCP.14m09081; PMID: 25562205.
  44. Sachs G.S., Greenberg W.M., Starace A., Lu K., Ruth A., Laszlovszky I., Nemeth G., Durgam S. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial // J Affect Disord. – 2015. – Vol. 174. – Pp. 296–302.
  45. McIntyre R.S., Masand P.S., Earley W., Patel M. Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials // J Affect Disord. – 2019. – Vol. 1, no. 257. – Pp. 600–606. – DOI: 10.1016/j.jad.2019.07.020; Epub 2019 Jul 5; PMID: 31344528.
  46. Ketter T.A., Sachs G.S., Durgam S., Lu K., Starace A., Laszlovszky I., Németh G. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study // J Affect Disord. – 2018. – Vol. 1, no. 225. – Pp. 350–356. – DOI: 10.1016/j.jad.2017.08.040; Epub 2017 Aug 18; PMID: 28843918
  47. Earley W., Durgam S., Lu K., Debelle M., Laszlovszky I., Vieta E., Yatham L.N. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies // J Affect Disord. – 2017. – Vol. 215. – Pp. 205–212. – DOI: 10.1016/j.jad.2017.03.032; Epub 2017 Mar 9; PMID: 28343051.
  48. Earley W., Durgam S., Lu K., Ruth A., Németh G., Laszlovszky I., Yatham L.N. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder // J Affect Disord. – 2018. – Vol. 15, no. 226. – Pp. 239–244. – DOI: 10.1016/j.jad.2017.09.040; Epub 2017 Sep 25; PMID: 29017067.
  49. Durgam S., Earley W., Lipschitz A. et al. An 8-week randomized, double-blind, placebocontrolled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression // Am J Psychiatry. – 2016. – Vol. 173. – Pp. 271–281.
  50. Earley W.R., Burgess M.V., Khan B., Rekeda L., Suppes T., Tohen M., Calabrese J.R. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study // Bipolar Disord. – 2020. – 22 (4). – Pp. 372–384. – DOI: 10.1111/bdi.12852; Epub 2019 Nov 6; PMID: 31628698; PMCID: PMC7318333.
  51. Earley W., Burgess M.V., Rekeda L., Dickinson R., Szatmári B., Németh G., McIntyre R.S., Sachs G.S., Yatham L.N. Cariprazine treatment of bipolar depression: A randomized double-blind placebo-controlled phase 3 study // Am J Psychiatry. – 2019. – Vol. 1, no. 176 (6). – Pp. 439–448. – DOI: 10.1176/appi.ajp.2018.18070824; Epub 2019 Mar 8; PMID: 30845817.
  52. Earley W.R., Burgess M., Rekeda L., Hankinson A., McIntyre R.S., Suppes T., Calabrese J.R., Yatham L.N. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression // J Affect Disord. – 2020. – Vol. 15, no. 263. – Pp. 386–395. – DOI: 10.1016/j.jad.2019.11.098; Epub 2019 Nov 22; PMID: 31969269
  53. Patel M., Jain R., Tohen M., Maletic V., Earley W.R., Yatham L.N. Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies // Int Clin Psychopharmacol. – 2021. – Vol. 1, no. 36 (2). – Pp. 76–83. – DOI: 10.1097/YIC.0000000000000344; PMID: 33230026; PMCID: PMC7846289.
  54. Pinto J.V., Saraf G., Vigo D. et al. Cariprazine in the treatment of bipolar disorder: A systematic review and meta-analysis // Bipolar Disord. – 2019. – Vol. 22 (4). – Pp. 360–371.
  55. Conus P., Macneil C., McGorry P.D. Public health significance of bipolar disorder: implications for early intervention and prevention // Bipolar Disord. – 2014. – Vol. 16 (5). – Pp. 548– 556. – DOI: 10.1111/bdi.12137; Epub 2013 Oct 16; PMID: 24127825.
  56. Merikangas K.R., Jin R., He J.-P., Kessler R.C., Lee S., Sampson N.A. et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative // Arch Gen Psychiatry. – 2011. – Vol. 68. – Pp. 241–251.
  57. McDonald K.C., Bulloch A.G.M., Duffy A., Bresee L., Williams J.V.A., Lavorato D.H. et al. Prevalence of bipolar I and II disorder in Canada // Can J Psychiatr. – 2015. – Vol. 60. – Pp. 151–156.
  58. Maina G., Albert U., Bellodi L., Colombo C., Faravelli C., Monteleone P. et al. Health-related quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes // J Clin Psychiatry. – 2007. – Vol. 68. – Pp. 207–212.
  59. MacQueen G.M., Young L.T. Bipolar II disorder: Symptoms, course, and response to treatment // Psychiatr Serv. – 2001. – Vol. 52. – Pp. 358–561.
  60. Swartz H.A., Rucci P., Thase M.E., Wallace M., Carretta E., Celedonia K.L. et al. Psychotherapy alone and combined with medication as treatments for bipolar II depression: a randomized controlled trial // J Clin Psychiatry. – 2018. – Vol. 79. – Pp. 7–15.
  61. Torres I.J., Boudreau V.G., Yatham L.N. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis // Acta Psychiatr Scand. – 2007. – Vol. 116. – Pp. 17–26.
  62. Robb J.C., Cooke R.G., Devins G.M., Young L.T., Joffe R.T. Quality of life and lifestyle disruption in euthymic bipolar disorder // J Psychiatr Res. – 1997. – Vol. 31. – Pp. 509–517.
  63. Baldessarini R.J., Vázquez G.H., Tondo L. Bipolar depression: a major unsolved challenge // Int J Bipolar Disord. – 2020. – Vol. 6, no. 8 (1). – P. 1. – DOI: 10.1186/s40345-019-0160-1; PMID: 31903509; PMCID: PMC6943098.
  64. Yatham L.N., Kennedy S.H., Parikh S.V. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder // Bipolar Disord. – 2018. – Vol. 20 (2). – Pp. 97–170. – DOI: 10.1111/bdi.12609; Epub 2018 Mar 14; PMID: 29536616; PMCID: PMC5947163.
  65. Vieta E., Berk M., Wang W., Colom F., Tohen M., Baldessarini R.J. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients // J Affect Disord. – 2009. – Vol. 119 (1–3). – Pp. 22–27. – DOI: 10.1016/j.jad.2009.02.028; Epub 2009 Mar 26; PMID: 19324419.
  66. Berk M., Brnabic A., Dodd S., Kelin K., Tohen M., Malhi G.S., Berk L., Conus P., McGorry P.D. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention // Bipolar Disord. – 2011. – Vol. 13 (1). – Pp. 87–98. – DOI: 10.1111/j.1399-5618.2011.00889.x; PMID: 21320256.
  67. Swann A.C., Lafer B., Perugi G., Frye M.A., Bauer M., Bahk W.M., Scott J., Ha K., Suppes T. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis // Am J Psychiatry. – 2013. – Vol. 170 (1). – Pp. 31–42. – DOI: 10.1176/appi.ajp.2012.12030301; PMID: 23223893.
  68. Tohen M., Calabrese J., Vieta E., Bowden C., Gonzalez-Pinto A., Lin D., Xu W., Corya S. Effect of comorbid anxiety on treatment response in bipolar depression // J Affect Disord. – 2007. – Vol. 104 (1–3). – Pp. 137–146. – DOI: 10.1016/j.jad.2007.03.014; Epub 2007 May 21; PMID: 17512607.
  69. Betzler F., Stöver L.A., Sterzer P., Köhler S. Mixed states in bipolar disorder - changes in DSM-5 and current treatment recommendations // Int J Psychiatry Clin Pract. – 2017. – Vol. 21 (4). – Pp. 244–258. – DOI: 10.1080/13651501.2017.1311921; Epub 2017 Apr 18; PMID: 28417647.
  70. Мосолов С.Н., Костюкова Е.Г., Ушкалова А.В. и др. Алгоритмы биологической терапии биполярного аффективного расстройств // Современная терапия психических расстройств. – 2013. – № 4. – С. 31–39.
  71. Garnham J., Munro A., Slaney C., MacDougall M., Passmore M., Duffy A. et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study // J Affect Disord. – 2007. – Vol. 104. – Pp. 185–190.
  72. Антонович Б.А. Применение карипразина при биполярном аффективном расстройстве // Современная терапия психических расстройств. – 2021. – № 1. – С. 34–43. – DOI: 10.21265/PSYPH.2021.46.92.005

Скачивания

Данные скачивания пока недоступны.